Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.37 -1.72 (-3.07%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Contact Levi &amp; Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1... 
Via Benzinga
Topics Stocks
Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today
Via Stocktwits
3 Magnificent Stocks Under $100 to Buy Right Now
You won't need a huge amount of cash to invest in these great pharma stocks. 
Via The Motley Fool
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Via Stocktwits
Topics Intellectual Property
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO
From DJS Law Group
Via Business Wire
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs
To gain an edge, this is what you need to know today. 
Via Benzinga
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story. 
Via The Motley Fool
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples. 
Via The Motley Fool
Topics World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025
From Berger Montague
Via GlobeNewswire
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
The latest data from the company's oral weight loss drug is bullish for the stock. 
Via The Motley Fool
Topics Economy
3 Reasons to Buy Novo Nordisk Stock Right Now
The pharmaceutical leader is gradually laying the groundwork for a strong rebound. 
Via The Motley Fool
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
 
Via Benzinga
Topics ETFs
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug. 
Via Investor's Business Daily
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.